TACKLING CHRONIC LIVER DISEASE

TACKLING CHRONIC LIVER DISEASE

NASH, hepatitis, cirrhosis, liver failure, cancer.

Half a billion people worldwide are at risk unless new therapies are found.

Introducing AI-POWR™

AI-POWR™ combines Artificial Intelligence, Machine Learning, and Deep Learning to decode disease, develop targeted therapies, and to select patients that will respond to Hepion therapies. Learn more >>

About Hepion Pharmaceuticals

Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV). The Company’s lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Currently in clinical phase development, CRV431 shows potential to play an important role in the overall treatment of liver disease – from triggering events through to end-stage disease.